TPTX » Topics » Revenues

This excerpt taken from the TPTX 10-Q filed Nov 9, 2006.

Revenues

          We had no revenue for the quarters ended September 30, 2006 and 2005. We had no revenue for the nine months ended September 30, 2006 and $403,000 in revenue for the nine months ended September 30, 2005. Revenue in 2005 was derived exclusively from the sale of research assays and fine chemicals at OXIS. The reduction in revenue in 2006 from prior year levels results from the fact that OXIS operations are no longer being consolidated with our results effective March 1, 2005 as discussed in Note 1 and 2 to the condensed consolidated financial statements.

This excerpt taken from the TPTX 10-Q filed Aug 8, 2006.

Revenues

                The Company had no revenue for the quarters ended June 30, 2006 and 2005. The Company had no revenue for the six months ended June 30, 2006 and $403,000 in revenue for the six months ended June 30, 2005. Revenue in 2005 was derived exclusively from the sale of research assays and fine chemicals at OXIS. The reduction in revenue in 2006 from prior year levels results from the fact that OXIS operations are no longer being consolidated with our results effective March 1, 2005 as discussed in Note 3 to the condensed consolidated financial statements.

This excerpt taken from the TPTX 10-Q filed May 10, 2006.

Revenues

The Company had no revenue for the quarter ended March 31, 2006 and $403,000 in revenue for the quarter ended March 31, 2005. Revenue in 2005 was derived exclusively from the sale of research assays and fine chemicals at OXIS. The reduction in revenue for the quarter March 31, 2006 from prior year levels results from the fact that OXIS operations are no longer being consolidated with our results effective March 1, 2005 as discussed in Note 2 to the condensed consolidated financial statements.

 

This excerpt taken from the TPTX 10-Q filed Nov 9, 2005.

Revenues

The Company had no revenue for the quarter ended September 30, 2005 and $954,000 for the quarter ended September 30, 2004. The Company had revenue of $403,000 and $1,865,000 for the nine months ended September 30, 2005 and 2004, respectively. Revenue in 2005 and 2004 was derived from the sale of research assays and fine chemicals at OXIS. In 2004, included in revenue is $450,000 Oxis received in licensing income. The reduction in revenue for the quarter and nine months ended September 30, 2005 from prior year levels results from the fact that OXIS operations are no longer being consolidated with our results effective March 1, 2005 as discussed in Note 1 to the condensed consolidated financial statements.

 

This excerpt taken from the TPTX 10-Q filed Aug 8, 2005.

Revenues

          The Company had no revenue for the quarter ended June 30, 2005 and $433,000 for the quarter ended June 30, 2004. The Company had revenue of $403,000 and $911,000 for the six months ended June 30, 2005 and 2004, respectively. Revenue in 2005 and 2004 was derived from the sale of research assays and fine chemicals at OXIS. The reduction in revenue for the quarter and six months ended June 30, 2005 from prior year levels results from the fact that OXIS operations are no longer being consolidated with our results effective March 1, 2005 as discussed in Note 1 to the condensed consolidated financial statements.                               

This excerpt taken from the TPTX 10-Q filed May 10, 2005.

Revenues

                The Company had revenue of $403,000 and $478,000 for the three months ended March 31, 2005 and 2004 respectively. Revenue in 2005 and 2004 was derived from the sale of research assays and fine chemicals at OXIS.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki